P.D. Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai, India.
J Arthroplasty. 2011 Oct;26(7):1128-34. doi: 10.1016/j.arth.2010.11.010. Epub 2011 Jan 21.
Although all the recent reports of the use of bisphosphonates in avascular necrosis of femoral head (AVNFH) have been encouraging, none has studied long-term effects of this novel therapy. We therefore performed a 10-year follow-up study of 40 patients (53 hips) of AVNFH treated with 3-year-long oral alendronate therapy. Rates of clinical failure defined as need for further surgical intervention, of radiologic progression for the Ficat-Arlet scale, and of collapse of femoral head showed marked reduction even at 10 years as compared to the historical data available for natural history of hips with untreated AVNFH. Alendronate given for 3 years maintains its beneficial effects for as long as 10 years and hence is a worthwhile option to postpone the need for arthroplasty in these young and active patients.
虽然最近所有关于双膦酸盐在股骨头缺血性坏死（AVNFH）中应用的报告都令人鼓舞，但没有一项研究探讨这种新疗法的长期效果。因此，我们对 40 例（53 髋）接受 3 年口服阿伦膦酸盐治疗的 AVNFH 患者进行了 10 年随访研究。与未经治疗的 AVNFH 髋关节自然史的现有历史数据相比，临床失败（定义为需要进一步手术干预）、Ficat-Arlet 分期的影像学进展和股骨头塌陷的发生率在 10 年内明显降低。阿伦膦酸盐治疗 3 年可维持长达 10 年的有益效果，因此对于这些年轻、活跃的患者，推迟关节置换的需求是一种有价值的选择。
